期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

原癌基因和抑癌基因在肺癌中的研究进展 被引量：2

下载PDF
导出
作者 祖金池 李文艳 段斐
机构地区 河北大学附属医院 河北医科大学基础医学院
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2009年第9期804-807,共4页 Cancer Research on Prevention and Treatment
基金 河北省科技攻关资助项目(20042761459) 保定市基金资助项目[04F001(4)] 河北省卫生厅基金资助项目(04251)
关键词 恶性肿瘤 肺癌 原癌基因 抑癌基因
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Kovalchuk O, Naumnik W, Serwicka A, et al, K-ras codon 12 mutations may be detected in serum of patients suffering from adeno-and large cell lung carcinoma. A preliminary report[J], Folia Histochem Cytobiol,2001,39(suppl 2) : 70- 72.
  • 2谭敏,宾晓农,陈家堃.痰脱落细胞ras基因突变在肺癌诊断中的意义[J].国际医药卫生导报,2007,13(14):4-7. 被引量：2
  • 3李希波,孙雪飞,尹秋伟,王善政.肺癌患者K-ras、FHIT基因异常与吸烟关系[J].中国公共卫生,2008,24(5):536-538. 被引量：3
  • 4Riely GJ, Kris MG, Rosenbaum D, et ai. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma[J]. Clin Cancer Res. 2008, 14 (18): 5731-5734.
  • 5Wu CC, Hsu HY, Liu HP, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications [ J ]. Cancer, 2008, 113 ( 11 ) : 3199- 3208.
  • 6Bachmann M, Kosan C, Xing PX, et al. The oncogenic serine/threonine pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25CD[J]. Int J Biochem Cell Biol,2006,38(3) : 430-443.
  • 7Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1(miR 1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1[J].J Biol Chem,2008, 283 (48) : 33394-33405.
  • 8Jung JS, Han SGL, Jo UH, et al. Single nucleotide Polymorphisms of Pim-1 in Korean lung cancer patients[J]. J Thorac Oncol,2007,2(8 suppl 4) :487.
  • 9Waenecke-Eberz U, Bollschweiler E, Derbber U. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases[J]. Oncol Rep. 2008,20(3): 619- 624.
  • 10Tiseo M, Loprevite M, Ardizzoni A. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer[J]. Curr Med Chem Anticancer Agents, 2004, 4 (2): 139-148.

二级参考文献13

  • 1Agusti C,Xaubet A,Monton C,et al.Induced sputum in the diagnosis of peripheral lung cancer not visible endoscopically[J].Respir Med,2001,95(10):822-826
  • 2Yakubouskaya MS,Spiegelman V,Luo FC,et al.High frequency of K-ras mutations in normal appea ring lung tissues and sputum of patients with lung cancer[J].Int Jcancer,1995,63(5):810-814
  • 3Crazians JL,Gamble GBN ewman NB,et al.Prognostic significance of K-ras mutation in patlents with resected stage Ⅰ and Ⅱ nonsmall lung cancer[J].J Clin Onco 1,1999;17(2):668-675
  • 4Copper CA,Carey FA,Bubb VJ,et al.The pattern of K-ras mutation in pulmonary adenocarcinoma diffines a new pathway of tumour development in the human lung[J].J Pathol,1997,181:401-404
  • 5Li ZH,Zheng J,weiss LM,et al.C-K-ras and p53 mutations occur very early in the adenocarci-noma of lung cancer[J].Am J Pathol,1994,144(2):303-309
  • 6Steven A Ahrendt,John r.Chow,Li-Hua Xu.et al.Molecular Detection of Tu-mor Cells in Bron-choalveolar Lavage Fluid From Patients With Early Stage Lung Cancer[J].Journal of the National Cancer Institute,1999,91(4):332-339
  • 7Ronai Z,YabubovskayaM S,Zhang E,et al.K-ras mutation in sputum of patients wi th or wi-thout lung cancer[J].T CellBiochem Supp 1,1996;25:172-176
  • 8Tyczynski JE,Bray F,Parkin DM.Lung cancer in Eutopein 2000:epidemiolngy,prevention,and early detection[J].Lancet Oncol,2003,(1):45-55.
  • 9Williams MD,Sandier AB.The epidemiology of lung cancer[J].Cancer Trear Res.2001,105:31-52.
  • 10Sngawa M,Saito Y,FujumuraS,et al.K-ras poit mutation occurs in the early stage of cancinogenesis in lung cancer[J].Br J of Cancer,1998,77(5):720-723.

共引文献20

同被引文献9

  • 1Lippman SM,Spitz MR. Lung cancer chemo prevention: an te- grated approach[J]. J Clin Oncol, 2001,19 (18 suppl) : 74s-82s.
  • 2Wang H,Nan L, Yu D, et al. Antisense anti-MDM2 oligonu- cleotide as a novel therapeutic approach to human breast canc- er:in vitro and in vivo activities and mechanisms[J]. Clin Cancer Res, 2001,7 (l 1 ) : 3613-3624.
  • 3Feng GH, Lili CJ, Cohen SN. TSC-101 Protein steady-state lev- el is regulated posttranslationally by an evolutionarily con- served COOH-terminal sequence. [J]. Cancer Res, 2000, 60 (6) : 1736-1741.
  • 4Cheng TH,Cohen SN. Human MDM2 is oforms translated dif- ferentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops[J]. Mol Cell Biol, 2007, 27 (1) : 111- 119.
  • 5Ventura A, Kirsch IX3, McLaughlin ME, et al. Restoration of p53 funtion leads to tumor regression in vivo[J]. Nature, 2007,445 ( 7128 ) : 661-665.
  • 6Li L,Liao J,Ruland J,et al. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback con- trol[J]. Proc Natl Acad Sei USA,2001,98(4) : 1619-1624.
  • 7Campbell PM,Der CJ.Oncogenic Ras and its role in tumor cell invasion and metastasis[].Seminars in Cancer Biology.2009
  • 8杨廷桐,武俊芳,李秀杰,范文艳,汪艳丽.非小细胞肺癌中p14ARF和mtp53蛋白表达与临床病理参数的关系[J].新乡医学院学报,2008,25(4):336-339. 被引量：1
  • 9杨廷桐,张骏,郑杰,吴秉铨.人小细胞肺癌P^(53)基因突变的研究[J].肿瘤防治研究,1998,25(6):445-447. 被引量：3

引证文献2

二级引证文献7

肿瘤防治研究
2009年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部